Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
KisqaliⓇ grows strongly across all regions
Increasing recognition of overall survival and quality of life benefits
Sales evolution
USD m, % CC
Ex-US
US
+49%
7
327
232
193
145
mBC monthly % NBRx share
63
Ibrance®
-KisqaliⓇ
1 GROWTH
YCE
AZ
KISQALI KL
-VerzenioⓇ
58
56
57
40
53
49
19
33 33
31 31
54
44
33
55
59
557
51
44
43
40
35
33
27
27
28
28
31 31
31
34
26 26
20
18
18
14
15
13 12
13 14
10
134
87
Q3 2021
Q3 2022
Sep Oct Nov Dec Jan Feb Mar Apr May Jun
2021
Jul Aug
2022
mBC Metastatic breast cancer NBRX - New to Brand prescriptions CDK Cyclin Dependent Kinase 1. Of CDK4/6 mBC market, monthly
10 Investor Relations | Q3 2022 Results
Sales accelerating: US NBRx
share 26% (vs. 10% PY)1
Driven by Kisqali's unique profile:
-
Only CDK4/6 with overall
survival benefit across
3 Ph3 studies
- Improved / maintained
quality of life in MBC
First head-to-head CDK4/6
study (vs. IbranceⓇ HARMONIA):
recruitment ongoing; final
analysis expected 2026
NATALEE adjuvant study primary
analysis expected H2 2023
NOVARTIS | Reimagining MedicineView entire presentation